Human Longevity develops longevity-focused technologies and services centered on an artificial intelligence health risk and recommendation platform. It operates a 100+ Longevity Care membership program designed to identify early stages of major age-related diseases and to increase healthspan and lifespan via its clinical care team and data platform. The program leverages precision-medicine inputs including whole-genome sequencing, whole-body and brain MRI, comprehensive cardiac evaluations, body composition analysis, advanced blood biomarkers, and wearables. By continually adding and analyzing client health data, the company aims to shift care from reactive to proactive, preventative, and personalized. The company plans to invest in additional longevity technologies, services, and new expansion sites globally. Human Longevity is headquartered in San Francisco, CA. Human Longevity operates the Health Nucleus intelligence platform, which combines specialized imaging, whole genome sequencing and other lab tests with machine learning and AI to generate precision health analytics. The company provides in-depth Health Nucleus assessments in La Jolla, CA, delivering risk analyses for cardiac, cancer, metabolic and cognitive issues. Core inputs to the platform include whole genome sequencing, brain and body MRI, cardiac CT (CAT) scans, metabolic tests and additional diagnostics. Human Longevity positions these integrated metrics as a comprehensive standard for measuring health and performance for physicians and patients. The company announced a $30 million financing to support its operations. Proceeds from the financing will be used to enhance the Health Nucleus intelligence platform. Human Longevity, Inc. (HLI) is a San Diego, CA–based genomics company led by co-founder and CEO J. Craig Venter, Ph.D., that aggregates whole-genome, phenotype and clinical data. Its core offerings include the HLI Health Nucleus, a genomic-enhanced clinical research center that combines whole genome sequencing, advanced clinical imaging and machine learning. The company is developing large-scale computing and machine-learning approaches to discover novel insights in medicine. HLI operates the HLI Knowledgebase, which currently contains more than 20,000 complete genomes coupled with phenotype data. Its business also includes a Comprehensive Cancer Program and other sequencing programs. HLI plans to use new funding to grow and expand these products and continue development of the Knowledgebase.

Total raised

$290M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2024